T. Alonso Gordoa

Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

J. García-Saenz, E. Díaz-Rubio, T. Alonso Gordoa, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

C. Porta, R. Motzer, T. Powles, 2021, The New England journal of medicine.

Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.

A. Ravaud, T. Powles, J. Carles, 2019, European urology.

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

C. Perna, T. Alonso Gordoa, R. Martin Huertas, 2019, Cancer management and research.

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%?

A. Lamarca, J. Strosberg, L. de Mestier, 2020, The oncologist.

The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

A. Carrato, J. Burgos Revilla, J. Lorca Álvaro, 2021, Therapeutic advances in urology.

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

R. García-Carbonero, I. Matos, J. Capdevila, 2019, British Journal of Cancer.

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

A. Carrato, F. Longo, J. Casado, 2022, European Journal of Cancer.

Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A).

M. Rebelatto, M. Hellmann, J. Diamond, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC).

J. Larkin, M. Atkins, V. Matveev, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

T. Powles, T. Choueiri, B. Melichar, 2023, The Lancet. Oncology.

New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies

E. Díaz Rubio, A. Gómez, J. Vázquez, 2015, Current Treatment Options in Oncology.

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

R. García-Carbonero, I. Matos, J. Capdevila, 2019, British Journal of Cancer.

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.

M. Atkins, A. Poprach, D. Cho, 2020, Journal of Clinical Oncology.